Cantor Fitzgerald Reiterates Overweight on Skye Bioscience, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Skye Bioscience (NASDAQ:SKYE) and maintained a $14 price target.
September 20, 2024 | 4:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Skye Bioscience, maintaining a $14 price target, indicating confidence in the company's potential.
The reiteration of an Overweight rating and a $14 price target by a reputable analyst suggests positive sentiment and potential upside for Skye Bioscience's stock. This could lead to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100